A Significant Unmet Need in Brain Cancer
Brain cancer, and particularly glioblastoma, is one of the most challenging cancers to treat due to its aggressive biology and the brain’s highly sensitive anatomy. Tumors infiltrate surrounding brain tissue and frequently recur, even after surgery, radiation, and chemotherapy. Because tumors are often located near critical areas responsible for movement, speech, and cognition, surgical removal and repeat radiation may be limited or not possible. As a result, patients with recurrent disease face few effective treatment options, and care is often focused on symptom management rather than long-term control.
Potential Benefits of Alpha DaRT for Brain Cancer
Treating brain cancer requires balancing therapeutic effect with preservation of neurological function. Alpha DaRT® was developed to address this unmet need as highly focused, intratumoral alpha-emitting radiotherapeutic. By delivering potent alpha particles directly within the tumor, Alpha DaRT is designed to concentrate its effect where it is needed most, while limiting exposure to surrounding healthy brain tissue. This localized approach has the potential to provide meaningful tumor control in an area where treatment options are extremely limited.
Potential benefits of Alpha DaRT include:
Intratumoral, localized treatment
designed to deliver alpha therapy directly within brain tumors
Alpha-particle therapy with very short range
concentrating effect in the tumor while limiting exposure to surrounding healthy brain tissue
Designed for tumors near critical brain structures
where surgical removal or repeat radiation may be limited
Potential activity in hypoxic and radioresistant tumor regions
which are less responsive to conventional photon-based radiation
Minimally invasive, stereotactic delivery
compatible with standard brain navigation systems
Single-procedure treatment approach
reducing the need for prolonged treatment courses
Integrates with existing neurosurgical and oncology workflows
supporting multidisciplinary care
Developed with preservation of neurological function
and quality of life in mind
Delivery of Alpha DaRT to Brain Tumors
Alpha DaRT sources are delivered to brain tumors using established neurosurgical techniques, similar to those used in a standard brain biopsy and other minimally invasive intracranial procedures. Treatment planning is based on high-resolution imaging to precisely define tumor location and guide source placement.
Using conventional brain navigation systems, a neurosurgeon inserts a stereotactic needle into the tumor along a planned trajectory. A unique applicator is then inserted, with the aim to deploy Radium-224 directly within the tumor, distributed in layers to achieve planned coverage without repeated needle insertions. After the desired coverage of the tumor has been achieved, the applicator is then removed, leaving the Radium-224 to decay naturally inside the tumor to deliver focused alpha therapy.
Frequently Asked Questions about Alpha DaRT for Brain Cancer
Why might someone consider the Alpha DaRT as a treatment for brain cancer?
Brain tumors, particularly aggressive tumors such as glioblastoma, often recur even after surgery, radiation, and chemotherapy. When this occurs, treatment options may become limited, especially if the tumor is located near critical areas of the brain where additional surgery or repeat radiation may carry increased risk.
Alpha DaRT is being investigated as a potential localized treatment approach for brain tumors, designed to deliver alpha radiation directly within the tumor. This intratumoral approach aims to concentrate the therapeutic effect in the tumor while limiting exposure to surrounding healthy brain tissue.
How is Alpha DaRT delivered in brain cancers?
lpha DaRT treatment for brain tumors is performed using established neurosurgical techniques similar to those used in minimally invasive brain biopsy procedures. Treatment planning begins with high-resolution imaging such as MRI or CT scans to accurately define the tumor and plan the insertion path.
Using stereotactic navigation systems, a neurosurgeon guides a needle into the tumor along a carefully planned trajectory. A dedicated applicator is then used to deploy radium-224 sources within the tumor in a controlled pattern designed to achieve coverage of the target area. After placement, the applicator is removed and the radium sources remain in the tumor to release alpha radiation locally.
How is Alpha DaRT designed to protect normal brain tissue?
Preserving neurological function is a major consideration in brain tumor treatment. Alpha DaRT uses alpha particles, which travel only a very short distance in tissue. When delivered directly inside the tumor, this short range is designed to help concentrate radiation within the tumor while limiting exposure to nearby healthy brain structures.
This localized radiation profile may be particularly important for tumors located near sensitive areas of the brain. The minimally invasive stereotactic delivery approach is also designed to reduce disruption to normal tissue compared with more extensive surgical procedures.
Treatment planning and placement are performed using imaging and navigation systems to help ensure accurate targeting of the tumor region.
Where can someone find the Alpha DaRT treatment for brain cancer in the U.S.?
Alpha DaRT is currently available at several leading research and medical centers in the U.S. in clinical trials, being studied as a treatment for recurrent glioblastoma. Alpha DaRT is not currently authorized for use or commercial sale outside of the context of an approved clinical trial.
Visit clinicaltrials.gov